ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/24
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational UpdateGlobeNewsWire • 08/06/24
ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024GlobeNewsWire • 07/30/24
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentGlobeNewsWire • 07/08/24
ADC Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/30/24
ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewsWire • 05/15/24
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/09/24
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/06/24
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded WarrantsGlobeNewsWire • 05/06/24
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/06/24
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone LymphomaGlobeNewsWire • 05/06/24
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaGlobeNewsWire • 04/04/24
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024GlobeNewsWire • 04/03/24
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/13/24
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/13/24
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes SummitGlobeNewsWire • 03/06/24